The supply contract with the company, which Unilife said it could not name, relates to the planned launch of a generic equivalent of an approved auto-immune therapy, the release stated.

Next year's implementation of a legally binding European Union directive that mandates European health care facilities use needle-stick prevention products played a significant role in the firm picking the Unifill syringe, according to the company.

Annual sales in the initial European geography are expected to reach volumes of up to 10 million units during the contract period, generating up to $15 million in revenue per year, the release stated.

Unilife shares are traded on the Nasdaq under the ticker symbol UNIS.